RRRoberto Righetto

Roberto Righetto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roberto Righetto has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Daniele Scartoni

    Proton Therapy Unit, S. Chiara Hospital - Azienda Provinciale per I Servizi Sanitari (APSS), Trento, Italy

    2 shared publications
  • Francesco Dionisi

    Radiation Oncology Unit, Istituto Regina Elena, IFO, Roma, Italy

    2 shared publications
  • Francesco Fracchiolla

    Proton Therapy Unit, S. Chiara Hospital - Azienda Provinciale per I Servizi Sanitari (APSS), Trento, Italy

    2 shared publications
  • Marco Schwarz

    Proton Therapy Unit, S. Chiara Hospital - Azienda Provinciale per I Servizi Sanitari (APSS), Trento, Italy; Trento Institute for Fundamental Physics and Applications (TIFPA), National Institute for Nuclear Physics, (INFN), Povo, Italy

    2 shared publications
  • Paolo Farace

    Proton Therapy Unit, S. Chiara Hospital - Azienda Provinciale per I Servizi Sanitari (APSS), Trento, Italy

    2 shared publications
  • Paolo Farace

    Section of Innovation Biomedicine - Department of Engineering for Innovation Medicine (DIMI), University of Verona, Verona, Italy

    2 shared publications

Latest Publications

  • Open Access

    Toxicity and Clinical Results after Proton Therapy for Pediatric Medulloblastoma: A Multi-Centric Retrospective Study

    by Alessandro Ruggi, Fraia Melchionda, Iacopo Sardi, Rossana Pavone, Linda Meneghello, Lidija Kitanovski, Lorna Zadravec Zaletel, Paolo Farace, Mino Zucchelli, Mirko Scagnet, et al.

    Medulloblastoma is the most common malignant brain tumor in children. Even if current treatment dramatically improves the prognosis, survivors often develop long-term treatment-related sequelae. The current radiotherapy standard for medulloblastoma is craniospinal irradiation with a boost to the primary tumor site and to any metastatic sites. Proton therapy (PT) has similar efficacy compared to traditional photon-based radiotherapy but might achieve lower toxicity rates. We report on our multi-centric experience with 43 children with medulloblastoma (median age at diagnosis 8.7 years, IQR 6.6, M/F 23/20; 26 high-risk, 14 standard-risk, 3 ex-infant), who received active scanning PT between 2015 and 2021, with a focus on PT-related acute-subacute toxicity, as well as some preliminary data on late toxicity. Most acute toxicities were mild and manageable with supportive therapy. Hematological toxicity was limited, even among HR patients who underwent hematopoietic stem-cell transplantation before PT. Preliminary data on late sequelae were also encouraging, although a longer follow-up is needed.


  • Technical challenges in the treatment of mediastinal lymphomas by proton pencil beam scanning and deep inspiration breath-hold

    by Roberto Righetto, Francesco Fracchiolla, Lamberto Widesott, Stefano Lorentini, Francesco Dionisi, Barbara Rombi, Daniele Scartoni, Sabina Vennarini, Marco Schwarz, Paolo Farace


  • Open Access

    Is it beneficial to use apertures in proton radiosurgery with a scanning beam? A dosimetric comparison in neurinoma and meningioma patients

    by Roberto Righetto, Francesco Fellin, Daniele Scartoni, Maurizio Amichetti, Marco Schwarz, Dante Amelio, Paolo Farace

    Purpose: To assess the dosimetric advantages of apertures in intracranial single fraction proton radiosurgery.Materials and methods: Six neuroma and 10 meningioma patients were investigated. For each patient, six plans were computed, with two spot spacing and three aperture settings (no apertures, 5 and 8 mm margin between aperture and clinical target volume [CTV]). All plans were optimized on the CTV with the same beam arrangement and the same single‐field robust optimization (2 mm setup errors, 3.5% range uncertainties). Robustness analysis was performed with 0.5 and 1.0 mm systematic setup errors and 3.5% range uncertainties. CTV coverage in the perturbed scenarios and healthy brain tissue sparing in the surrounding of the CTV were compared.Results: Meningiomas were larger and at a shallow depth than neuromas. In neuromas, spot spacing did not affect OAR doses or the robustness of CTV coverage and the apertures reduced brain dose without any significant impact on CTV robustness. In meningiomas, smaller spot spacing produced a reduction in brain V5Gy and improved robustness of CTV coverage; in addition, an 8 mm margin aperture reduced low and medium brain tissue doses without affecting robustness in the 0.5 mm perturbed scenario. A 5 mm margin aperture caused a reduction of plan robustness.Conclusion: The optimal use of apertures is a trade‐off between sparing of low and medium dose to the healthy brain and robustness of target coverage, also depending on size and depth of the lesion.


  • Accurate proton treatment planning for pencil beam crossing titanium fixation implants

    by Roberto Righetto, Luis Pazos Clemens, Stefano Lorentini, Francesco Fracchiolla, Carlo Algranati, Francesco Tommasino, Francesco Dionisi, Marco Cianchetti, Marco Schwarz, Paolo Farace